Results 271 to 280 of about 53,729,253 (423)

Substance use among healthcare professionals: A cross-sectional study in Kenya. [PDF]

PLOS Glob Public Health
Shah J, Smith C, Mostert C, Khakali L, Merali Z, Ali SK.   +5 more
europepmc   +1 more source

Retention Behavior of Lipophilic Components in Biological Substances in Silica Gel Liquid Chromatography Using Aqueous Binary Solvent Systems

, 1989
Shoji Hara, Tatsuhiko Ando, Yoshiyuki Nakayama   +2 more
openalex   +2 more sources

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

Unseen dualities: underdiagnosis of substance use disorders in borderline personality disorder. [PDF]

Front Psychiatry
Nabel J, Bertele S, Stapel B, Scharn N, Kahl KG.   +4 more
europepmc   +1 more source

Utilisation de substances organiques des fins de mise en vegetation de rejects miniers acides (The use of organic substances in the revegetation of acid mine tailings)

, 1989
Antoine Karam, L. M. Azzaria
openalex   +1 more source

Interplay of integrins and selectins in metastasis

Molecular Oncology, EarlyView.
Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva, Ashot Nersisyan, Alexander Tonevitsky   +2 more
wiley   +1 more source

Prevalence of Impairing Substance Use in Injured Drivers.

JAMA Netw Open
Brubacher JR, Erdelyi S, Chan H, Simmons S, Atkinson P, Besserer F, Clarke DB, Davis P, Daoust R, Émond M, Eppler J, Lee JS, MacPherson A, Magee K, Mercier E, Ohle R, Parsons M, Rao J, Rowe BH, Taylor J, Vaillancourt C, Wishart I.   +21 more
europepmc   +1 more source

Quality indicators for substance use disorder care: a scoping review protocol. [PDF]

BMJ Open
Richards TD, Kirkham J, Lorenzetti D, Anderson J, Bahji A, Allami Y, Crockford D, Dyson MP, Ghosh SM, Hodgins D, Messier G, Vik S, Seitz DP.   +12 more
europepmc   +1 more source

Alcohol and Other Substance Use in STD Clinic Patients

, 1994
Jonathan M. Zenilman, Edward W. Hook, Mary Shepherd, Patricia Smith, Anne Rompalo, David D. Celentano   +5 more
openalex   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source